MYnd Analytics Invited to Present Updated Data at Military Research Symposium

MISSION VIEJO, Calif., Aug. 29, 2017 -- MYnd Analytics, Inc. (NASDAQ:MYND), a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error, will present a poster at today’s 2017 Military Health Services Research Symposium.

The poster, entitled “Can ‘Big Data’ Help Physicians Improve Treatment for Psychological Trauma? Results from an ongoing Registry Trial (n = 10,700)” covers additional studies and evidence findings from independent reviewers, including:

• Results from previous trials of PEER demonstrate a “strong effect” that is 2 to 3-fold higher than that reported in antidepressant drug trials.
• These trial results represent a higher level of evidence than has previously been demonstrated in trials performed with commonly prescribed depression medication.
• Results are consistent across four randomized controlled trials, which demonstrates generalizability of results.

George Carpenter, MYnd CEO, said, “Evidence for PEER continues to build and we are grateful for the military's continuing interest in how ‘big data’ can improve quality of care for service members with mental health issues.”

About MYnd Analytics, Inc.

MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG).  Based on the Company’s original physician developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications. 

To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.

Forward-looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as MYnd's ability to successfully expand into various market channels, the ability of its products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses and MYnd's ability to expand globally in areas where there is an opportunity to improve treatment in mental health, as well as those risks and uncertainties set forth in MYnd's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact:
Stan Wunderlich
Investor Relations, CFSG1
800-625-2236
[email protected]
www.launchpadir.net